Galectin Therapeutics INC Stock: price and management transactions · United States · SEC (Form 4)

About Galectin Therapeutics INC

Galectin Therapeutics Inc. (NASDAQ: GALT) is a United States-based clinical-stage biotechnology company listed on the NASDAQ market. The company is headquartered in Norcross, Georgia, in the Atlanta metropolitan area. It was founded in July 2000, originally as Pro-Pharmaceuticals, Inc., and later reoriented around galectin science, becoming a focused developer of therapies aimed at fibrotic, inflammatory, and malignant diseases. For French-speaking investors evaluating the name, Galectin should be viewed as a classic development-stage biotech: it has a science-driven pipeline, limited or no commercial revenue, and a business model highly dependent on clinical readouts, regulatory interactions, and access to capital. Galectin’s core strategy is built around galectins, especially galectin-3, which the company believes play an important role in biological and pathological processes such as fibrosis, inflammation, and cancer progression. Its lead asset is belapectin, a therapeutic candidate being advanced primarily in metabolic dysfunction-associated steatohepatitis (MASH, previously NASH) cirrhosis and portal hypertension. This is the company’s most important value driver and the program most closely watched by the market. In addition to the lead liver-disease franchise, the company has disclosed earlier-stage development efforts in severe atopic dermatitis, moderate-to-severe plaque psoriasis, and combination immunotherapy approaches for advanced melanoma and other malignancies. As a result, Galectin’s competitive position is not based on an existing commercial portfolio, but on the potential differentiation of its galectin-targeting platform. Geographically, the business is U.S.-centric, with its corporate base in Georgia and historical research ties to the Boston area. Its market position remains that of a small-cap specialty biotech competing in a crowded and highly uncertain development environment. The upside case rests on whether belapectin can establish meaningful clinical benefit in a high-unmet-need liver disease setting and whether management can translate that science into a viable regulatory and partnering path. The downside case is the usual one for single-asset-heavy biotechs: delays, equivocal data, funding pressure, and dilution risk. Recent company updates have centered on the NAVIGATE program for belapectin. During 2025 and into 2026, management highlighted additional biomarker analyses, ongoing presentation activity at major liver-disease conferences, and continued dialogue with the FDA regarding next steps. The company also reported quarterly losses and a relatively modest cash position, reinforcing the importance of execution and financing discipline. For market participants tracking SEC Form 4 insider transactions, Galectin is also a name with regular insider-filing activity, which is typical for a closely followed U.S.-listed biotechnology issuer.